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Post-acute and chronic phases after acute coronary syndrome (ACS) present with several challenges 
for patients and physicians alike. Guidelines have been developed to help physician in the decision 
making process, but at times they are at variance from more recent studies and the current clinical 
practice.  
Prognosis after myocardial infarction 
After ACS patients remain at risk for adverse cardiovascular events: according to the GRACE 
Registry1 at 5 years after ACS total and cardiovascular mortality were 20% and 13%; new 
myocardial infarctions (MI), stroke and need for revascularization occurred respectively in 9%, 8% 
and 17%. Patients with stable angina on the other hand have a yearly mortality rate between 1% and 
2.5%,2 and a rate of 0.6%-2.7% of adverse coronary events.3,4 Every day clinical practice seems to 
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depict a bleaker picture: the Primary Prevention Study reported survival for patients with previous 
MI and stable angina of 34% and 53% respectively.5 The prognosis of chronic ischemic heart 
disease varies considerably according to the baseline anatomical, clinical and functional 
characteristics as well as the choice of therapeutic intervention. After ACS patients can be divided 
in two basic categories: patients with high risk of heart failure, presenting a negative evolution from 
the immediate post-acute phase characterized by progressive unfavorable remodeling; and patients 
at high risk for new thrombotic events leading to recurrent ischemia or anew necrosis. There are 
some angiography-derived parameters known to be associated with high risk of ischemic 
recurrence, such as the number of coronary vessels with significant stenosis and the incomplete 
revascularization. Recently, the SYNTAX score has been devised to characterize coronary anatomy 
according to the number and the complexity of the coronary lesions, deriving a score for each lesion 
and a total score for the patient. This system has provided important standardization in the 
definition of coronary anatomy but has the limitation of not taking into account other important 
variables such as the ejection fraction, the myocardial vitality of the coronary territory and the 
presence of co-morbidity, such renal insufficiency and chronic obstructive pulmonary disease. The 
ARTS-II study and the ACUITY trial brought convincing evidence supporting the use of scoring 
system which combine clinical and angiographic parameters as the most useful in predicting a 
prognosis and re-affirmed that diabetes mellitus, renal insufficiency, peripheral arterial disease, 
history of angina or previous MI and multi vessels disease are associated with a very high residual 
cardiovascular risk. 
 
Therapy of MI in patients with multi vessels disease according to Guidelines 
According to the 2015 ESC Guidelines6, in patients after non-ST-elevation MI (NSTEMI) are 
recommended lifestyle modification measures and optimal medical therapy to improve the long-
term prognosis. With IA recommendation are included: high-dose statins; ACE-inhibitors/ARB in 
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diabetes, systolic dysfunction or hypertension; beta-blockers particularly in patients with ejection 
fraction <40%; the latter recommendation has been recently challenged in Randomized Clinical 
Trials (RTC) after NSTEMI without systolic dysfunction. 
The 2014 American Heart Association Guidelines7 confirmed the need for risk factor control and 
change in lifestyle. Beta-blockers without intrinsic sympathycomimetic activity (metoprolol 
succinate, bisoprolol, carvedilol) are recommended for NSTEMI with decreased ejection fraction 
after clinical stabilization and in absence of contraindications. Non-dyhidropyridinic calcium 
antagonists are recommended for patients with recurrent angina when beta-blockers are 
contraindicated in patients without significant left ventricular dysfunction. ACE-inhibitors and anti-
aldosterone drugs preserve their usual indications; with the level IIB recommendation ACE-
inhibitors are given in all patients with multiple site atherosclerotic disease; as a second line anti 
angina treatment, for symptoms control, nitrates and ranolazine are also recommended.  
The 2013 AHA Guidelines8 for ST elevation MI (STEMI) are similar in the recommendation for 
beta-blockers, ACE-inhibitors, antialdosterone drugs and statins to the NSTEMI Guidelines but 
there is no mention of calcium antagonists. For anterior MI there is a IA recommendation for ACE-
inhibitor, whereas the level drops to IIB level for the use of ACE-inhibitor in all other acute MI 
patients.  
There is wide agreement in all Guidelines as to the usefulness of cardiac rehabilitation to help in 
control of cardiovascular risk factor and compliance to the medical treatment, especially in patients 
with a high risk profile. There are no specific indications as to the proper treatment for patients with 
multi vessels disease.  
 
Pharmacological therapy of MI during the post-acute and chronic phases 
Antiplatelets and cholesterol lowering drugs  
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Dual antiplatelet therapy and statins are the most effective drugs in terms of improving the 
prognosis after MI. In this field, the most topical issues are the choice of the molecule to be given, 
the duration of treatment, the need for different associations, and the LDL cholesterol target to be 
aimed for; these therapies are treated extensively in other parts of this volume. 
 
Beta-blockers  
One of the major and controversial innovation in 2013 ESC Guidelines2 has been the withdrawal of 
beta-blockers as drugs able to improve prognosis, whereas, in the 2006 edition, received a class IA 
recommendation after MI. Presently they received a class IIaC recommendation only in patients 
with documented residual ischemia >10%. In the AHA Guidelines for chronic ischemic heart 
disease9 beta-blockers received a class IB recommendation for the first 3 years after the MI and a 
class IIbC in the long term10 (Table 1). 
 This action has been taken following publication of studies documenting that beta-blockers did not 
have a significant effect in decreasing cardiovascular events in patients without left ventricular 
dysfunction. In the REACH Registry11 patients who received beta-blockers did not have reduction 
in the risk of cardiovascular events at 44 months' mean follow up. This study though lacked of 
specific information as to the beta-blocking molecule utilized and its dose; ventricular function was 
also not considered. Data remain very discordant: in a large sample study beta-blockers 
significantly reduced mortality for cardiovascular causes12, while a meta-analysis comparing trials 
performed before and after the advent of coronary reperfusion, concluded that, in the post-
reperfusion era, beta-blockers have no impact on mortality, but increase risk of heart failure and 
cardiogenic shock13. However, both AHA and ESC Guidelines recommend starting beta-blocker 
treatment during hospitalization to reduce ischemia, re-infarction and complex ventricular 
arrhythmias. According to COMMIT/CCS-214, beta-blockers should be started later in patients with 
acute ventricular dysfunction, hypotension or at high risk of cardiogenic shock (Table 1). 
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To support the therapeutic value of beta-blockers there is the demonstration of a favorable 
prognosis associated with low resting heart rate: in 2005 was proved that a resting heart rate <62 
bpm was an independent predictor of lower mortality.15 Similarly it was demonstrated that for each 
10 beats reduction of resting heart rate there was 20% decrease in all cause mortality, 30% of 
cardiovascular mortality, 39% of sudden death and 21% of non fatal MI.16  
 
Calcium-antagonists  
Non dyhidropyridinic calcium antagonists (CA) are effective in reducing cardiovascular risk in 
patients after MI without left ventricular dysfunction by decreasing the heart rate. Data for this class 
of drugs derive from somewhat dated studies and in clinical practice they are now used when there 
are absolute contraindication to beta-blockers such as in patients with COPD and reversible 
bronchoconstriction.  
Dyhidropyridinic CA are attested in Guidelines efficacy both at a single drug and in association 
with beta-blockers, 17 when they have demonstrated, although in a few older studies, to provide for 
a better exercise tolerance and a trend toward a lower rate of cardiovascular events.18 
 
ACE/ARB 
There is ample evidence of the beneficial effect of ACE-inhibitor after MI with reduction of 
mortality and cardiovascular events in patients with left ventricular dysfunction, without the same 
uniformity of data in patients with preserved ejection fraction. ACE-inhibitors are also effective in 
the post MI remodeling process.  
The evidence that angiotensin receptor blockers (ARB) are non-inferior to ACE-inhibitors in 
reducing morbidity and mortality after MI stems from the VALIANT study, conducted in patients 
with reduced EF. 
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Nitrates 
Various nitrates formulations are widely used in clinical practice after MI. The ESC Guidelines for 
chronic ischemic heart disease debate against the routine use of nitrates in the long-term. In fact, 
besides the notorious tolerance phenomenon, there is evidence suggesting that long-term use of 
nitrates is associated with endothelial dysfunction. Fifteen years ago was observed that patients 
chronically assuming long acting nitrates after ACS had a worst prognosis.18 During the following 
years numerous evidences became available tightening the isosorbide-5-mononitrate (I5MN) to 
endothelial dysfunction through a mechanism mediated by a production of oxygen free radical.19 
Recent animal experiments documented an increased expression of endothelin-1 activating adenin 
dinucleotidefosphate vascular and phagocites oxidase  with production of oxygen free radicals.20 
Accordingly, the Guidelines gives to long acting nitrates a class IIB recommendation for symptoms 
control and class IA for the same purpose to short acting nitrates. Despite these recommendations 
Italian doctors still prescribe long acting nitrates in over 70% of the patients. 
 
Ivabradine 
Ivabradine is a specific inhibitor of the If channels in the sinus atrial node that reduces angina and 
ameliorates exercise tolerance. It is used in patients with sinus rhythm to decrease the heart rate in a 
dose-dependent fashion, thus decreasing myocardial ischemia without affecting systemic blood 
pressure, myocardial contractility, intra-cardiac conduction or ventricular repolarization.  
In patients with heart failure and ischemic heart disease, the drug provided for a significant 
reduction of the risk of cardiovascular death and recurrent hospital admission. 
In 2014 the SIGNIFY trial21, designed to evaluate the effectiveness of this drug in patients with 
chronic stable ischemic heart disease without heart failure, showed that patients taking the drug did 
not have significant reduction in cardiovascular deaths or non fatal MI, despite significant reduction 
in heart rate of 10 bpm. In treated patients with moderate to severe degrees of angina, instead, there 
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was evidence for an increase in cardiovascular deaths and non fatal MI, and development of 
symptomatic bradycardia and atrial fibrillation. Several hypotheses were raised to explain these 
data:  too high dose of the drug (10 mg bid),  the absence of correlation between reduction of heart 
rate and reduction of events in patients with preserved EF, the deleterious effect of the association 
of ivabradine with calcium antagonists such as verapamil.22 
Accordingly, whether an adjustment of the beta-blockers dosage is recommended before starting 
ivabradine in patients without left ventricular dysfunction, ivabradine is very useful after MI in 
patients with systolic dysfunction for symptomatic treatment of ischemic heart disease.23 
 
Ranolazine 
Ranolazine is useful in reducing angina symptoms in patients with chronic myocardial ischemia due 
to its ability to block the slow entry current of sodium in the cells thus reducing the sodium and 
calcium intracellular overload and consumption of ATP and oxygen thus reducing the electrical and 
mechanical dysfunction brought by ischemia. The efficacy of this drug in improving symptoms 
control was proven in the registration studies. In the MERLIN-TIMI3624, conducted in patients with 
ACS / NSTEMI, ranolazine had significantly reduced episodes of recurrent ischemia compared with 
placebo but not mortality, but in the subgroup of patients with previous diagnosis of angina, the 
primary end point (cardiovascular death, MI, or recurrent ischemia) was significantly reduced in the 
treated group. 
Other studies demonstrated the efficacy of this drug in patients with diabetes mellitus and in women 
in particular. Accordingly, the drug is used in combination with other drugs when those are not 
sufficient for symptoms control or when beta-blockers or calcium antagonists are contraindicated.  
The RIVER-PCI trial25 failed to demonstrate an effect of this drug on the prognosis thus raising 
inappropriate doubts on its efficacy in symptomatic patients after coronary revascularisation. 
However, it arose critical considerations on the trial design and the conclusions derived from it, 
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partly raised by the same authors. For these reasons, the therapeutic indication of ranolazine in 
symptomatic chronic ischemic heart disease remains completely unchanged. 
 
Non pharmacological therapy 
Too often underestimated, but of fundamental importance, is the organization of a secondary 
prevention program that follows the patient after discharge from the hospital, with provision for  
tailored treatment and follow up  and education about disease and therapy. To support this concept, 
the OASIS 526 demonstrated that just 6 months after discharge patient in optimal medical therapy 
had a 3.8 time risk of death, recurrent infarct or stroke when they resumed the smoking habit and 
did not follow diet and physical activity recommendation as compared to patients who did. 
As indicated by The Italian Consensus Document of the National Cardiologists Associations27  
patients with a high risk profile (see for example the multivessels disease) should be referred to 
Cardiac Rehabilitation and secondary prevention programs. In reality STEMI and NSTEMI patients 
who are referred to rehabilitation in Italy are still a small part (less than 17% in the Blitz4 Quality 
ANMCO Registry).  
The compliance with pharmacological treatment is also very important but in clinical practice up to 
50% of the patients failed to follow their drug regimen during the first year after MI. According to 
the CRUSADE-ACTION Registry, explanations could be absence of a follow-up planning or 
rehabilitation program and lack of adequate instructions  to the patients about the goal  of the 
treatment prescribed. This has also being emphasized by the Agency for Healthcare Research and 
Quality of the United States that  in “medication reconciliation” deals also with the fact that many 
patients after discharge continue to assume prescriptions given by other doctors before the event; 
this, in some situations, could contribute to pharmacological interaction causing side effect at time 
even severe or ineffectiveness of the new treatment. 
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Accordingly, implementing those strategies in a well thought out simple and effective program 
designed to assist the patients in a long term could be as valuable as the drugs prescribed. 28 
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Table 1: International Guidelines recommendations for beta-blockers therapy. 
   
 STEMI NSTEMI-UA Stable CAD  
American Heart 
Association/American 
College of Cardiology 
Start treatment during the 
first 24 hours if no 
contraindications   
(see text) 
Class I evidence B 
As for STEMI 
Class I evidence A 
After acute MI  continue 
treatment for the next 3 
years if EF normal 
Class I evidence B 
After acute MI if EF 
normal: chronic treatment  
Class IIb evidence C 
If EF <40% : chronic 
treatment 
Class I evidence A 
As treatment for symptoms 
relief 
Class I evidence A 
European Society of 
Cardiology 
Start treatment during the 
first hospitalization if  no 
contraindication (see text) 
than continue indefinitely  
Class IIa evidence B 
If EF  <40% start 
treatment as soon as 
feasible than continue 
indefinitely 
Class I evidence A 
Start treatment during 
the first hospitalization if  
no contraindication (see 
text) than continue 
indefinitely  
Class I evidence B 
Contraindicated with  
vasospastic angina 
Class IIa evidence B 
 
 
Microvascular angina 
Class I evidence B 
As treatment for symptoms 
relief 
Class  I evidence A 
 
Not present in secondary 
prevention 
 
 
 
